BXRX.Q Share Price Performance
US$0.000001
-0.00 (-99.50%)
Price US$0.000001
Share PriceUS$0.000001
Baudax Bio, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
BXRX.Q Community Narratives
There are no narratives available yet.
Recent BXRX.Q News & Updates
Baudax Bio, Inc. Key Details
Last Reported Earnings
Sep 30, 2023
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Baudax Bio, Inc. Competitors
Snowflake Analysis
About BXRX.Q
- Founded
- 2019
- Employees
- n/a
- CEO
- WebsiteView website
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 0.8%
- 3 Months: 8.3%
- 1 Year: 17.8%
- Year to Date: 15.4%
The Utilities sector gained 3.1% while the market remained flat over the last week. As for the longer term, the market has risen 18% in the past 12 months. Earnings are forecast to grow by 15% annually. Market details ›